Pharma stocks led the market today, with the Nifty Pharma index rising nearly 2%, after reports said the US FDA has reached out to Indian pharmaceutical manufacturers for potential supply of critical cancer drugs, including ifosfamide injections.

The rally was broad-based, with Dr. Reddy’s gaining up to 2.6%, Cipla nearly 3%, Laurus Labs over 3%, Zydus Lifesciences around 2.8%, Sun Pharma over 1.5%, while Piramal Pharma surged more than 8% on the supply-opportunity trigger.

Trigger

• US FDA reportedly approached the Indian Drug Manufacturers’ Association to identify Indian companies capable of supplying cancer drug ifosfamide.
• The US is facing shortages after reduced capacity at Baxter International, a key supplier of ifosfamide.
• Reports suggest the US FDA may even consider supply from non-FDA-registered Indian facilities or products approved outside the US, given the shortage situation.
• A weaker rupee against the US dollar is also supporting sentiment in export-linked pharma names.

The market is reacting positively because this is a rare situation where Indian pharma could get fast-track export opportunities into a high-value regulated market. Ifosfamide is used in treatment of cancers such as testicular, bladder and lung cancer, and a supply shortage in the US gives Indian manufacturers a chance to capture emergency procurement demand, provided they have the required capacity, sterile injectable capability and acceptable compliance standards.

The larger read-through is positive for export-oriented pharma companies, especially those with oncology, injectables, complex generics and US-facing manufacturing infrastructure. However, the benefit will not be uniform across the sector. Companies with relevant product capability, clean regulatory track record and ability to supply quickly will be better placed than generic formulation players without exposure to oncology injectables.

The rally also comes at a time when pharma has already been seeing defensive buying. In a market worried about global growth, IT demand and geopolitical risks, pharma offers a combination of export earnings, defensive demand, specialty-drug optionality and currency tailwind. The rupee’s recent weakness against the dollar adds to the sentiment, as a large part of Indian pharma revenue is export-linked.